-
公开(公告)号：US20170197992A1
公开(公告)日：2017-07-13
申请号：US15326381
申请日：2015-07-13
申请人： Michael HÖPFNER , Bernhard BIERSACK , Rainer SCHOBERT , Katharina MAHAL , CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN , UNIVERSITÄT BAYREUTH
IPC分类号： C07F1/00 , C07D233/64
CPC分类号： C07F1/00 , C07D233/61 , C07D233/64 , C07F1/12
摘要： The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
-
公开(公告)号：US09868750B2
公开(公告)日：2018-01-16
申请号：US15326381
申请日：2015-07-13
申请人： CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN , UNIVERSITÄT BAYREUTH , Michael Höpfner , Bernhard Biersack , Rainer Schobert , Katharina Mahal
IPC分类号： C07F1/00 , C07D233/64
CPC分类号： C07F1/00 , C07D233/61 , C07D233/64 , C07F1/12
摘要： The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
-
搜索结果
2 条记录 (耗时 0.009 秒)
